Latest News and Press Releases
Want to stay updated on the latest news?
-
REDWOOD CITY, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
-
REDWOOD CITY, Calif., Sept. 13, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
-
Demcizumab and Tarextumab Randomized Phase 2 Data Expected 1H 2017 Anti-TIGIT IND Accepted; GITRL-Fc IND Expected 1H 2017 OncoMed Management to Host Conference Call/Webcast this Afternoon at 4:30...
-
Enters 2017 with $184.6 Million in Cash Potential for Five Program Opt-ins Totaling Over $170M Anti-TIGIT (I/O#2) IND Filed REDWOOD CITY, Calif., Jan. 05, 2017 (GLOBE NEWSWIRE) -- OncoMed...
-
Ends Quarter with $207 Million Cash Enrollment Complete in Phase 2 Trials for Demcizumab and Tarextumab;On Track for Data in 1H 2017 OncoMed Management to Host Conference Call/Webcast this...
-
REDWOOD CITY, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical development-stage biopharmaceutical company focused on discovering and developing...
-
REDWOOD CITY, Calif., Aug. 30, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical development-stage biopharmaceutical company focused on discovering and developing...
-
OncoMed Management to Host Conference Call/Webcast this Afternoon at 4:30 p.m. ET/1:30 p.m. PT Highlights AACR Presentations - Including Novel GITRL-Fc Candidate Clinical Data on Vantictumab,...
-
REDWOOD CITY, Calif., March 16, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) will present new data related to its clinical and preclinical anti-cancer stem cell and...
-
REDWOOD CITY, Calif., Jan. 22, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology...